Oxcarbazepine Patent Expiration
Oxcarbazepine is Used for managing partial-onset seizures. It was first introduced by Novartis Pharmaceuticals Corp
Oxcarbazepine Patents
Given below is the list of patents protecting Oxcarbazepine, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Oxtellar Xr | US10220042 | Modified release preparations containing oxcarbazepine and derivatives thereof | Apr 13, 2027 | Supernus Pharms |
| Oxtellar Xr | US11166960 | Modified release preparations containing oxcarbazepine and derivatives thereof | Apr 13, 2027 | Supernus Pharms |
| Oxtellar Xr | US11896599 | Modified release preparations containing oxcarbazepine and derivatives thereof | Apr 13, 2027 | Supernus Pharms |
| Oxtellar Xr | US7722898 | Modified-release preparations containing oxcarbazepine and derivatives thereof | Apr 13, 2027 | Supernus Pharms |
| Oxtellar Xr | US7910131 | Method of treating seizures using modified release formulations of oxcarbazepine | Apr 13, 2027 | Supernus Pharms |
| Oxtellar Xr | US8617600 | Modified release preparations containing oxcarbazepine and derivatives thereof | Apr 13, 2027 | Supernus Pharms |
| Oxtellar Xr | US8821930 | Modified release preparations containing oxcarbazepine and derivatives thereof | Apr 13, 2027 | Supernus Pharms |
| Oxtellar Xr | US9119791 | Modified release preparations containing oxcarbazepine and derivatives thereof | Apr 13, 2027 | Supernus Pharms |
| Oxtellar Xr | US9351975 | Modified release preparations containing oxcarbazepine and derivatives thereof | Apr 13, 2027 | Supernus Pharms |
| Oxtellar Xr | US9370525 | Modified release preparations containing oxcarbazepine and derivatives thereof | Apr 13, 2027 | Supernus Pharms |
| Oxtellar Xr | US9855278 | Modified release preparations containing oxcarbazepine and derivatives thereof | Apr 13, 2027 | Supernus Pharms |
| Trileptal |
US8119148 (Pediatric) | Suspension comprising oxcarbazepine |
Jun 19, 2021
(Expired) | Novartis |
| Trileptal | US8119148 | Suspension comprising oxcarbazepine |
Dec 19, 2020
(Expired) | Novartis |
| Trileptal |
US7037525 (Pediatric) | Oxacarbazepine film-coated tablets |
Aug 12, 2018
(Expired) | Novartis |
| Trileptal | US7037525 | Oxacarbazepine film-coated tablets |
Feb 12, 2018
(Expired) | Novartis |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Oxcarbazepine's patents.
Latest Legal Activities on Oxcarbazepine's Patents
Given below is the list recent legal activities going on the following patents of Oxcarbazepine.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Expire Patent Critical | 25 Mar, 2024 | US8119148 |
| Maintenance Fee Reminder Mailed Critical | 09 Oct, 2023 | US8119148 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 08 Aug, 2019 | US8119148 |
| Expire Patent Critical | 30 May, 2014 | US7037525 |
| Recordation of Patent Grant Mailed Critical | 21 Feb, 2012 | US8119148 |
| Patent Issue Date Used in PTA Calculation Critical | 21 Feb, 2012 | US8119148 |
| Issue Notification Mailed Critical | 01 Feb, 2012 | US8119148 |
| Dispatch to FDC | 27 Jan, 2012 | US8119148 |
| Dispatch to FDC | 17 Jan, 2012 | US8119148 |
| Application Is Considered Ready for Issue Critical | 17 Jan, 2012 | US8119148 |
Oxcarbazepine's Family Patents
Explore Our Curated Drug Screens
Oxcarbazepine Generic API Manufacturers
Several generic applications have been filed for Oxcarbazepine. The first generic version for Oxcarbazepine was by Glenmark Pharmaceuticals Ltd and was approved on Oct 9, 2007. And the latest generic version is by Aurobindo Pharma Ltd and was approved on Apr 30, 2025.
Given below is the list of companies who have filed for Oxcarbazepine generic, along with the locations of their manufacturing plants worldwide.
1. AJANTA PHARMA LTD
Ajanta Pharma Ltd has filed for 3 different strengths of generic version for Oxcarbazepine. Given below are the details of the strengths of this generic introduced by Ajanta Pharma Ltd.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 300MG | tablet, extended release | Prescription | ORAL | AB | Feb 22, 2024 |
| 150MG | tablet, extended release | Prescription | ORAL | AB | Feb 22, 2024 |
| 600MG | tablet, extended release | Prescription | ORAL | AB | Feb 22, 2024 |
Manufacturing Plant Locations New
Ajanta Pharma Ltd's manufacturing plants are situated in 1 country - India. Given below are the details of these plant locations as well as the firm names of Ajanta Pharma Ltd as present at those locations.
| Country | City | Firm Name | ||
|---|---|---|---|---|
| India |
| |||
2. ALKEM LABS LTD
Alkem Laboratories Ltd has filed for 1 generic for Oxcarbazepine. Given below are the details of the strengths of this generic introduced by Alkem Labs Ltd.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 300MG/5ML | suspension | Prescription | ORAL | AB | Mar 18, 2023 |
3. AMNEAL PHARMS
Amneal Pharmaceuticals has filed for 1 generic for Oxcarbazepine. Given below are the details of the strengths of this generic introduced by Amneal Pharms.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 300MG/5ML | suspension | Prescription | ORAL | AB | Sep 17, 2012 |
4. ANI PHARMS
Ani Pharmaceuticals Inc has filed for 3 different strengths of generic version for Oxcarbazepine. Given below are the details of the strengths of this generic introduced by Ani Pharms.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 150MG | tablet | Prescription | ORAL | AB | Dec 11, 2007 |
| 600MG | tablet | Prescription | ORAL | AB | Dec 11, 2007 |
| 300MG | tablet | Prescription | ORAL | AB | Dec 11, 2007 |
5. ANNORA PHARMA
Annora Pharma Private Ltd has filed for 3 different strengths of generic version for Oxcarbazepine. Given below are the details of the strengths of this generic introduced by Annora Pharma.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 300MG | tablet | Prescription | ORAL | AB | Jan 11, 2022 |
| 600MG | tablet | Prescription | ORAL | AB | Jan 11, 2022 |
| 150MG | tablet | Prescription | ORAL | AB | Jan 11, 2022 |
Manufacturing Plant Locations New
Annora Pharma's manufacturing plants are situated in 1 country - India. Given below are the details of these plant locations as well as the firm names of Annora Pharma as present at those locations.
| Country | City | Firm Name | ||
|---|---|---|---|---|
| India |
| |||
6. APOTEX
Apotex Inc has filed for 3 different strengths of generic version for Oxcarbazepine. Given below are the details of the strengths of this generic introduced by Apotex.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 300MG | tablet, extended release | Prescription | ORAL | AB | Jul 13, 2023 |
| 150MG | tablet, extended release | Prescription | ORAL | AB | Jul 13, 2023 |
| 600MG | tablet, extended release | Prescription | ORAL | AB | Jul 13, 2023 |
Manufacturing Plant Locations New
Apotex's manufacturing plants are situated in 3 countries - United States, Canada, India. Given below are the details of these plant locations as well as the firm names of Apotex as present at those locations.
| Country | City | Firm Name | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States |
| |||||||||||||
| Canada |
| |||||||||||||
| India |
| |||||||||||||
7. AUCTA
Aucta Pharmaceuticals Inc has filed for 1 generic for Oxcarbazepine. Given below are the details of the strengths of this generic introduced by Aucta.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 300MG/5ML | suspension | Prescription | ORAL | AB | Nov 30, 2022 |
8. AUROBINDO PHARMA LTD
Aurobindo Pharma Ltd has filed for 3 different strengths of generic version for Oxcarbazepine. Given below are the details of the strengths of this generic introduced by Aurobindo Pharma Ltd.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 150MG | tablet, extended release | Prescription | ORAL | AB | Apr 30, 2025 |
| 300MG | tablet, extended release | Prescription | ORAL | AB | Apr 30, 2025 |
| 600MG | tablet, extended release | Prescription | ORAL | AB | Apr 30, 2025 |
Manufacturing Plant Locations New
Aurobindo Pharma Ltd's manufacturing plants are situated in 1 country - India. Given below are the details of these plant locations as well as the firm names of Aurobindo Pharma Ltd as present at those locations.
| Country | City | Firm Name | ||
|---|---|---|---|---|
| India |
| |||
9. BIOCON PHARMA
Biocon Pharma Inc has filed for 1 generic for Oxcarbazepine. Given below are the details of the strengths of this generic introduced by Biocon Pharma.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 300MG/5ML | suspension | Prescription | ORAL | AB | Mar 1, 2024 |
Manufacturing Plant Locations New
Biocon Pharma's manufacturing plants are situated in 1 country - India. Given below are the details of these plant locations as well as the firm names of Biocon Pharma as present at those locations.
| Country | City | Firm Name | ||
|---|---|---|---|---|
| India |
| |||
10. BIONPHARMA
Bionpharma Inc has filed for 1 generic for Oxcarbazepine. Given below are the details of the strengths of this generic introduced by Bionpharma.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 300MG/5ML | suspension | Prescription | ORAL | AB | Nov 4, 2022 |
Manufacturing Plant Locations New
Bionpharma's manufacturing plants are situated in 1 country - United States. Given below are the details of these plant locations as well as the firm names of Bionpharma as present at those locations.
| Country | City | Firm Name | ||
|---|---|---|---|---|
| United States |
| |||
11. BRECKENRIDGE PHARM
Breckenridge Pharmaceutical Inc has filed for 3 different strengths of generic version for Oxcarbazepine. Given below are the details of the strengths of this generic introduced by Breckenridge Pharm.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 150MG | tablet | Prescription | ORAL | AB | Jan 11, 2008 |
| 300MG | tablet | Prescription | ORAL | AB | Jan 11, 2008 |
| 600MG | tablet | Prescription | ORAL | AB | Jan 11, 2008 |
Manufacturing Plant Locations New
Breckenridge Pharm's manufacturing plants are situated in 1 country - United States. Given below are the details of these plant locations as well as the firm names of Breckenridge Pharm as present at those locations.
| Country | City | Firm Name | ||||
|---|---|---|---|---|---|---|
| United States |
| |||||
12. CHARTWELL RX
Chartwell Rx Sciences Llc has filed for 1 generic for Oxcarbazepine. Given below are the details of the strengths of this generic introduced by Chartwell Rx.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 300MG/5ML | suspension | Prescription | ORAL | AB | Jun 21, 2021 |
13. GLENMARK PHARMS LTD
Glenmark Pharmaceuticals Ltd has filed for 3 different strengths of generic version for Oxcarbazepine. Given below are the details of the strengths of this generic introduced by Glenmark Pharms Ltd.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 300MG | tablet | Prescription | ORAL | AB | Oct 9, 2007 |
| 150MG | tablet | Prescription | ORAL | AB | Oct 9, 2007 |
| 600MG | tablet | Prescription | ORAL | AB | Oct 9, 2007 |
14. HETERO LABS LTD III
Hetero Labs Ltd Unit Iii has filed for 1 generic for Oxcarbazepine. Given below are the details of the strengths of this generic introduced by Hetero Labs Ltd Iii.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 300MG/5ML | suspension | Prescription | ORAL | AB | Oct 20, 2023 |
15. HIKMA
Hikma Pharmaceuticals Usa Inc has filed for 4 different strengths of generic version for Oxcarbazepine. Given below are the details of the strengths of this generic introduced by Hikma.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 150MG | tablet | Discontinued | ORAL | N/A | Oct 9, 2007 |
| 300MG | tablet | Discontinued | ORAL | N/A | Oct 9, 2007 |
| 600MG | tablet | Discontinued | ORAL | N/A | Oct 9, 2007 |
| 300MG/5ML | suspension | Discontinued | ORAL | N/A | Oct 3, 2012 |
Manufacturing Plant Locations New
Hikma's manufacturing plants are situated in 3 countries - United States, Portugal, Jordan. Given below are the details of these plant locations as well as the firm names of Hikma as present at those locations.
| Country | City | Firm Name | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| United States |
| |||||||||
| Portugal |
| |||||||||
| Jordan |
| |||||||||
16. JUBILANT CADISTA
Jubilant Cadista Pharmaceuticals Inc has filed for 3 different strengths of generic version for Oxcarbazepine. Given below are the details of the strengths of this generic introduced by Jubilant Cadista.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 600MG | tablet | Discontinued | ORAL | N/A | Jan 25, 2010 |
| 300MG | tablet | Discontinued | ORAL | N/A | Jan 25, 2010 |
| 150MG | tablet | Discontinued | ORAL | N/A | Jan 25, 2010 |
Manufacturing Plant Locations New
Jubilant Cadista's manufacturing plants are situated in 1 country - United States. Given below are the details of these plant locations as well as the firm names of Jubilant Cadista as present at those locations.
| Country | City | Firm Name | ||
|---|---|---|---|---|
| United States |
| |||
17. KANCHAN HLTHCARE
Kanchan Healthcare Inc has filed for 1 generic for Oxcarbazepine. Given below are the details of the strengths of this generic introduced by Kanchan Hlthcare.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 300MG/5ML | suspension | Prescription | ORAL | AB | Feb 14, 2024 |
18. RENEW PHARMS
Renew Pharmaceuticals Ltd has filed for 1 generic for Oxcarbazepine. Given below are the details of the strengths of this generic introduced by Renew Pharms.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 300MG/5ML | suspension | Discontinued | ORAL | N/A | Jul 9, 2021 |
19. RICONPHARMA LLC
Riconpharma Llc has filed for 3 different strengths of generic version for Oxcarbazepine. Given below are the details of the strengths of this generic introduced by Riconpharma Llc.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 150MG | tablet, extended release | Prescription | ORAL | AB | Nov 22, 2024 |
| 300MG | tablet, extended release | Prescription | ORAL | AB | Nov 22, 2024 |
| 600MG | tablet, extended release | Prescription | ORAL | AB | Nov 22, 2024 |
Manufacturing Plant Locations New
Riconpharma Llc's manufacturing plants are situated in 1 country - United States. Given below are the details of these plant locations as well as the firm names of Riconpharma Llc as present at those locations.
| Country | City | Firm Name | ||
|---|---|---|---|---|
| United States |
| |||
20. RUBICON
Rubicon Research Private Ltd has filed for 4 different strengths of generic version for Oxcarbazepine. Given below are the details of the strengths of this generic introduced by Rubicon.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 150MG | tablet | Prescription | ORAL | AB | Mar 5, 2024 |
| 600MG | tablet | Prescription | ORAL | AB | Mar 5, 2024 |
| 300MG | tablet | Prescription | ORAL | AB | Mar 5, 2024 |
| 300MG/5ML | suspension | Prescription | ORAL | AB | Aug 30, 2022 |
Manufacturing Plant Locations New
Rubicon's manufacturing plants are situated in 3 countries - United States, Canada, India. Given below are the details of these plant locations as well as the firm names of Rubicon as present at those locations.
| Country | City | Firm Name | ||||
|---|---|---|---|---|---|---|
| United States |
| |||||
| Canada |
| |||||
| India |
| |||||
21. SUN PHARM INDS
Sun Pharmaceutical Industries Ltd has filed for 3 different strengths of generic version for Oxcarbazepine. Given below are the details of the strengths of this generic introduced by Sun Pharm Inds.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 150MG | tablet | Prescription | ORAL | AB | Oct 9, 2007 |
| 300MG | tablet | Prescription | ORAL | AB | Oct 9, 2007 |
| 600MG | tablet | Prescription | ORAL | AB | Oct 9, 2007 |
22. SUN PHARM INDS LTD
Sun Pharmaceutical Industries Ltd has filed for 1 generic for Oxcarbazepine. Given below are the details of the strengths of this generic introduced by Sun Pharm Inds Ltd.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 300MG/5ML | suspension | Prescription | ORAL | AB | Jun 26, 2009 |
23. TARO
Taro Pharmaceutical Industries Ltd has filed for 3 different strengths of generic version for Oxcarbazepine. Given below are the details of the strengths of this generic introduced by Taro.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 300MG | tablet | Prescription | ORAL | AB | Nov 15, 2007 |
| 600MG | tablet | Prescription | ORAL | AB | Nov 15, 2007 |
| 150MG | tablet | Prescription | ORAL | AB | Nov 15, 2007 |
Manufacturing Plant Locations New
Taro's manufacturing plants are situated in 3 countries - United States, Israel, Canada. Given below are the details of these plant locations as well as the firm names of Taro as present at those locations.
| Country | City | Firm Name | ||||
|---|---|---|---|---|---|---|
| United States |
| |||||
| Israel |
| |||||
| Canada |
| |||||
24. ZYDUS
Zydus Worldwide Dmcc has filed for 3 different strengths of generic version for Oxcarbazepine. Given below are the details of the strengths of this generic introduced by Zydus.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 600MG | tablet | Discontinued | ORAL | N/A | Jul 3, 2023 |
| 300MG | tablet | Discontinued | ORAL | N/A | Jul 3, 2023 |
| 150MG | tablet | Discontinued | ORAL | N/A | Jul 3, 2023 |
Manufacturing Plant Locations New
Zydus's manufacturing plants are situated in 2 countries - India, United States. Given below are the details of these plant locations as well as the firm names of Zydus as present at those locations.
| Country | City | Firm Name | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| India |
| |||||||||||||||||||||||
| United States |
| |||||||||||||||||||||||